High viral suppression and low attrition in healthy HIV-infected patients initiated on ART with CD4 above 500 cells/µL in a program setting in Uganda

Background The World Health Organization recommends antiretroviral therapy (ART) for all HIV-infected patients at all CD4 counts. However, there are concerns that asymptomatic patients may have poorer viral suppression and high attrition. Objectives We sought to determine attrition and viral suppression among healthy HIV-infected patients initiated on ART in program settings. Methods This cross-sectional study enrolled ART-experienced patients attending two PEPFAR-supported, high-volume clinics in Kampala, Uganda. Eligible patients were >18 years and had completed at least six months on ART. Participants were interviewed on socio-demographics, ART history and plasma viral load (VL) determined using Abbott Real-time. Predictors of viral suppression (<75 copies/ml) were determined using multivariate logistic regression. Results Overall, 267 participants were screened, 228 were eligible and 203 (89%) retained in care (visit within 90 days). Of the 203 participants, 115 (56.7%) were key-populations. Viral suppression was achieved in 173 patients (85%; 95% CI, 80.3%–90.1%). The factors associated with viral suppression were prior VL tests (AOR 6.98; p-value <0.001) and receiving care from a general clinic (AOR 5.41; p=0.009). Conclusion Asymptomatic patients initiated on ART with high baseline CD4 counts, achieve high viral suppression with low risk of attrition. VL monitoring and clinic type are associated with viral suppression.

[1]  M. Siedner,et al.  ART adherence and viral suppression are high among most non‐pregnant individuals with early‐stage, asymptomatic HIV infection: an observational study from Uganda and South Africa , 2019, Journal of the International AIDS Society.

[2]  M. Petersen,et al.  Factors predictive of successful retention in care among HIV-infected men in a universal test-and-treat setting in Uganda and Kenya: A mixed methods analysis , 2019, PloS one.

[3]  N. McGrath,et al.  Universal test and treat is not associated with sub‐optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial , 2018, Journal of the International AIDS Society.

[4]  R. Wanyenze,et al.  Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014–July 2015 , 2017, BMC Infectious Diseases.

[5]  N. Ford,et al.  Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring. , 2017, The Lancet. Infectious diseases.

[6]  P. Vernazza,et al.  Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades , 2016, BMJ Global Health.

[7]  W. Andiman,et al.  Frequent Episodes of Detectable Viremia in HIV Treatment-Experienced Children is Associated with a Decline in CD4+ T-cells Over Time. , 2016, Journal of AIDS & clinical research.

[8]  W. Miller,et al.  The HIV Care Continuum among Female Sex Workers: A Key Population in Lilongwe, Malawi , 2016, PloS one.

[9]  C. Beyrer,et al.  HIV treatment cascade in MSM, people who inject drugs, and sex workers , 2015, Current opinion in HIV and AIDS.

[10]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[11]  R. Salamon,et al.  A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. , 2015, The New England journal of medicine.

[12]  S. Karim Overcoming Impediments to Global Implementation of Early Antiretroviral Therapy , 2015 .

[13]  D. Nash,et al.  Risk factors for loss to follow-up prior to ART initiation among patients enrolling in HIV care with CD4+ cell count ≥200 cells/μL in the multi-country MTCT-Plus Initiative , 2015, BMC Health Services Research.

[14]  T. Quinn,et al.  Durable Suppression of HIV-1 after Virologic Monitoring-Based Antiretroviral Adherence Counseling in Rakai, Uganda , 2015, PloS one.

[15]  W. Fawzi,et al.  Predictors of Nonadherence to Antiretroviral Therapy among HIV-Infected Adults in Dar es Salaam, Tanzania , 2015, Journal of the International Association of Providers of AIDS Care.

[16]  M. Boily,et al.  Antiretroviral Therapy Uptake, Attrition, Adherence and Outcomes among HIV-Infected Female Sex Workers: A Systematic Review and Meta-Analysis , 2014, PloS one.

[17]  D. Havlir,et al.  Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/&mgr;l in rural Uganda , 2014, AIDS.

[18]  Jeffrey N. Martin,et al.  CD4+ cell count at antiretroviral therapy initiation and economic restoration in rural Uganda , 2014, AIDS.

[19]  N. Shaffer,et al.  Is Option B+ the best choice? , 2013, The Lancet.

[20]  B. Tran,et al.  Determinants of antiretroviral treatment adherence among HIV/AIDS patients: a multisite study , 2013, Global health action.

[21]  M. Siedner,et al.  Higher Baseline CD4 Cell Count Predicts Treatment Interruptions and Persistent Viremia in Patients Initiating ARVs in Rural Uganda , 2013, Journal of acquired immune deficiency syndromes.

[22]  H. Coovadia,et al.  Is Option B+ the best choice? , 2013, The Lancet.

[23]  Curtis Cooper,et al.  Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. , 2012, The Journal of infectious diseases.

[24]  A. Ingram,et al.  Governmentality and security in the US President’s Emergency Plan for AIDS Relief (PEPFAR) , 2010 .